SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet. 2005; 366: 13031314.
  • 2
    Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer. 2002; 2: 10.
  • 3
    Falkson G, MacIntyre JM, Moertel CG. Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer. Cancer. 1984; 54: 965969.
  • 4
    Glimelius B, Hoffman K, Sjoden PO, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol. 1996; 7: 593600.
  • 5
    Gallardo J, Rubio B, Villanueva L, Barajas O. Gallbladder cancer, a different disease that needs individual trials. J Clin Oncol. 2005; 23: 77537754; author reply, 54–55.
  • 6
    Kubicka S, Rudolph KL, Tietze MK, Lorenz M, Manns M. Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas. Hepatogastroenterology. 2001; 48: 783789.
  • 7
    Lozano R, Patt Y, Hassan M, Frome A, Vauthey J, Ellis L, et al. Oral capecitabine (Xeloda) for the treatment of hepatobiliary cancers (hepatocellular carcinoma, cholangiocarcinoma and gallbladder). Proc Am Soc Clin Oncol. 2000; 19: 264. Abstract 1025.
  • 8
    Reyes-Vidal J, Gallardo J, Yanez E. Gemcitabine and cisplatin in the treatment of patients with unresectable or metastatic galbladder cancer: results of the phase II Gocchi study 2000–13. Proc Am Soc Clin Oncol. 2003; 22: 273. Abstract 1095.
  • 9
    Lee GW, Kang JH, Kim HG, Lee JS, Lee JS, Jang JS. Combination chemotherapy with gemcitabine and cisplatin as first-line treatment for immunohistochemically proven cholangiocarcinoma. Am J Clin Oncol. 2006; 29: 127131.
  • 10
    Kim TW, Chang HM, Kang HJ, et al. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer. Ann Oncol. 2003; 14: 11151120.
  • 11
    Nehls O, Klump B, Arkenau HT, et al. Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial. Br J Cancer. 2002; 87: 702704.
  • 12
    Nehls O, Klump B, Arkenau HT, Hass HG, Greschiniok A, Gregor M, et al. Multicenter phase II trial of oxaliplatin plus capecitabine (XELOX) in advanced biliary system adenocarcinomas (study CCC/GBC-01). Proc Am Soc Clin Oncol. 2003; 22: 280. Abstract 1126.
  • 13
    Julka PK, Puri T, Rath GK. A phase II study of gemcitabine and carboplatin combination chemotherapy in gallbladder carcinoma. Hepatobiliary Pancreat Dis Int. 2006; 5: 110114.
  • 14
    Knox JJ, Hedley D, Oza A, et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol. 2005; 23: 23322338.
  • 15
    Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205216.
  • 16
    Andre T, Reyes-Vidal JM, Fartoux L, et al. EXIBIT: an international multicenter phase II trial of gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer. Proc Am Soc Clin Oncol. 2006; Vol. 24. Abstract 4135.
  • 17
    Valle JM, Wasan H, Jouhson P, et al. Gemcitabine, alone or in combination with cisplatin, in patients with advanced or metastatic cholangiocarcinoma (CC) and other biliary tract tumors: a multicenter, randomized phase II (the UK ABC-01) study. Proc Am Soc Clin Oncol–Gastrointestinal Cancers Symposium. 2006; Vol. 24. Abstract 98.
  • 18
    Philip PA, Mahoney MR, Allmer C, et al. Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol. 2006; 24: 30693074.
  • 19
    Iyer RV, Gibbs DL, Soehnlein N, et al. A phase II study of gemcitabine (G) and capecitabine (C) in advanced cholangiocarcinoma (CC) and gallbladder carcinoma (GBC). Proc Am Soc Clin Oncol. 2005; Vol. 23. Abstract 4230.
  • 20
    Cho JY, Paik YH, Chang YS, et al. Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma. Cancer. 2005; 104: 27532758.
  • 21
    Lee MA, Woo IS, Kang JH, Hong YS, Lee KS. Gemcitabine and cisplatin combination chemotherapy in intrahepatic cholangiocarcinoma as second-line treatment: report of four cases. Jpn J Clin Oncol. 2004; 34: 547550.
  • 22
    Stemmler J, Heinemann V, Schalhorn A. Capecitabine as second-line treatment for metastatic cholangiocarcinoma: a report of two cases. Onkologie. 2002; 25: 182184.
  • 23
    Kornek GV, Schuell B, Laengle F, et al. Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. Ann Oncol. 2004; 15: 478483.
  • 24
    Ducreux M, Van Cutsem E, Van Laethem JL, et al. A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial. Eur J Cancer. 2005; 41: 398403.
  • 25
    Rao S, Cunningham D, Hawkins RE, et al. Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer. Br J Cancer. 2005; 92: 16501654.
  • 26
    Lozano R, Patt Y, Hassan M, et al. Oral capecitabine (Xeloda) for the treatment of hepatobiliary cancers (hepatocellular carcinoma, cholangiocarcinoma and gallbladder cancer). Proc Am Soc Clin Oncol. 2000; 19: 264.
  • 27
    Gallardo JO, Rubio B, Fodor M, et al. A phase II study of gemcitabine in gallbladder carcinoma. Ann Oncol. 2001; 12: 14031406.
  • 28
    Taieb J, Mitry E, Boige V, et al. Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma. Ann Oncol. 2002; 13: 11921196.
  • 29
    Kuhn R, Hribaschek A, Eichelmann K, Rudolph S, Fahlke J, Ridwelski K. Outpatient therapy with gemcitabine and docetaxel for gallbladder, biliary, and cholangiocarcinomas. Invest New Drugs. 2002; 20: 351356.
  • 30
    Eng C, Ramanathan RK, Wong MK, et al. A Phase II trial of fixed dose rate gemcitabine in patients with advanced biliary tree carcinoma. Am J Clin Oncol. 2004; 27: 565569.